



Company Announcement

Nykode Therapeutics Announces Upcoming Presentations at AACR 2026 and NextGen Biomed 2026

- *Poster session on lead program abi-suva at AACR and scientific presentations on the individualized cancer vaccine (VB10.NEO) and the tolerance program at NextGen Biomed*

Oslo, Norway, March 18, 2026 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced upcoming presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting and NextGen Biomed 2026.

The AACR Annual Meeting will take place April 17–22, 2026 in San Diego, California, and NextGen Biomed 2026 will be held March 24–26, 2026 in London, United Kingdom.

Presentation Details:

AACR Poster Session (abi-suva)

Session title: Phase I Clinical Trials

Title: *Immunogenicity of the therapeutic HPV16-specific cancer vaccine abipapogene suvaplasmid (VB10.16) in combination with pembrolizumab given as 1L treatment for HPV16+ PD-L1+ r/m oropharyngeal cancer: preliminary results from phase 1 of the VB-C-03 trial*

Location: Poster Section 50

Poster Board Number: 9

Date: April 21, 2026

Time: 09:00 AM – 12:00 PM PDT

NextGen Biomed Presentation (VB10.NEO)

Title: *VB10.NEO: The Journey of a Clinically Validated Individualized Cancer Therapy from Tumour Biopsy to Vaccine Administration*

Date: March 24, 2026

Time: 11:40-12:00 GMT

NextGen Biomed Presentation (Tolerance):

Title: *Development Of APC-Targeted Antigen-Specific Immune Tolerance Therapies For Autoimmune Diseases*

Date: March 25, 2026

Time: 12:00-12:25 GMT



The presentation slides will be available after the presentations at the Company's webpage: <https://nykode.com/research-and-development/scientific-papers-and-presentations/>

About Nykode Therapeutics

Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode's modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode's lead product candidates are abi-suva, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of late-line r/m cervical cancer. Abi-suva is currently being further developed in first line head and neck cancer with the randomized Abili-T trial with interim results within 2027. VB10.NEO, an individualized cancer neoantigen immunotherapy, has been investigated in two trials with more than 10 different indications.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics' shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at <http://www.nykode.com>.

Forward-looking statements for Nykode Therapeutics

This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:

IR@nykode.com

Nykode Therapeutics ASA

Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway